DarioHealth Corp.
DRIO
$0.6301
$0.00811.30%
| Weiss Ratings | DRIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | DRIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | DRIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.00 | |||
| Price History | DRIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -1.82% | |||
| 30-Day Total Return | -8.68% | |||
| 60-Day Total Return | -18.98% | |||
| 90-Day Total Return | -33.68% | |||
| Year to Date Total Return | -23.25% | |||
| 1-Year Total Return | -60.62% | |||
| 2-Year Total Return | -83.37% | |||
| 3-Year Total Return | -89.28% | |||
| 5-Year Total Return | -89.67% | |||
| 52-Week High % Change | -67.77% | |||
| 52-Week Low % Change | 11.07% | |||
| Price | DRIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.93 | |||
| 52-Week Low Price | $0.56 | |||
| 52-Week Low Price (Date) | Jan 29, 2025 | |||
| 52-Week High Price (Date) | May 17, 2024 | |||
| Valuation | DRIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 23.75M | |||
| Enterprise Value | 25.48M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.95 | |||
| Earnings Per Share Growth | -53.78% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.09 | |||
| Price/Book (Q) | 0.33 | |||
| Enterprise Value/Revenue (TTM) | 1.11 | |||
| Price | $0.63 | |||
| Enterprise Value/EBITDA (TTM) | -0.47 | |||
| Enterprise Value/EBIT | -0.42 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | DRIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 40.42M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | DRIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | -- | |||
| Address | 322 W 57th St New York, NY 10019 | |||
| Website | www.dariohealth.com | |||
| Country | United States | |||
| Year Founded | 2011 | |||
| Profitability | DRIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -260.98% | |||
| Profit Margin | -205.62% | |||
| Management Effectiveness | DRIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -34.74% | |||
| Return on Equity | -- | |||
| Income Statement | DRIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 23.05M | |||
| Total Revenue (TTM) | 23.05M | |||
| Revenue Per Share | $0.57 | |||
| Gross Profit (TTM) | 14.04M | |||
| EBITDA (TTM) | -53.97M | |||
| EBIT (TTM) | -60.16M | |||
| Net Income (TTM) | -47.40M | |||
| Net Income Avl. to Common (TTM) | -47.40M | |||
| Total Revenue Growth (Q YOY) | 111.00% | |||
| Earnings Growth (Q YOY) | 21.62% | |||
| EPS Diluted (TTM) | -0.95 | |||
| EPS Diluted Growth (Q YOY) | 49.25% | |||
| Balance Sheet | DRIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 15.55M | |||
| Cash Per Share (Q) | $0.38 | |||
| Total Current Assets (Q) | 29.53M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 58.51M | |||
| Current Ratio (Q) | 1.567 | |||
| Book Value Per Share (Q) | $1.87 | |||
| Total Assets (Q) | 109.95M | |||
| Total Current Liabilities (Q) | 18.85M | |||
| Total Debt (Q) | 30.49M | |||
| Total Liabilities (Q) | 51.44M | |||
| Total Common Equity (Q) | 58.51M | |||
| Cash Flow | DRIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -9.00M | |||
| Cash from Financing (TTM) | 20.21M | |||
| Net Change in Cash (TTM) | -28.01M | |||
| Levered Free Cash Flow (TTM) | -14.28M | |||
| Cash from Operations (TTM) | -39.17M | |||
